Table 6 AlloHCT for r/r MCL in patient exposed to BTKi: retrospective studies.
EBMT 2019 [99] | UK/Italy R-BAC [100] | EBMT 2025 [44] | |
|---|---|---|---|
N | 22 | 11 | 64 |
Period | 2013–2016 | 2015–2019 | 2014–2020 |
Age (years; median (range)) | 59 (45-69) | 62 (43-67) | >60 |
PS > 1 (ECOG) | 0 | n.a. | n.a. |
High-risk featuresa | |||
Ki-67 ≥ 30% | n.a. | n.a. | 65% |
Blastoid/pleomorph. | n.a. | n.a. | 54% |
Prior lines/median (range) | 2 (1–5) | n.a. | 3 (1–5) |
Prior autoHCT | 86% | n.a. | 44% |
BTKi refractory | 18–27% | 100% | n.a. |
Donor | n.a. | ||
MRD | 27% | 27% | |
Unrelated | 73% | 49% | |
Haplo | - | 23% | |
Cord blood | - | 2% | |
Conditioning | n.a. | ||
Reduced | 73% | 91% | |
Myeloablative | 27% | 9% | |
TBI-based | 32% | 31% | |
Non-relapse mortality (12mo) | 5% | 0 | 21% |
Relapse (12mo) | 19% | 0 | 28% |
PFS (12mo/24mo) | 76%/76% | 100%/80% | 50%/44%b |
OS (12mo/24mo) | 86%/86% | 100% | 59%/51%b |
Median follow-up (months) | 13 (2–29) | 10 | 34 (27–50) |
